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Abstract: Neurotoxicity is the most frequent dose-limiting toxicity of oxaliplatin. Acute
sensory neurotoxicity manifests as rapid onset of cold-induced distal dysesthesia and/or
paresthesia, sometimes accompanied by cold-dependent muscular contractions of the
extremities or the jaw. The symptoms, often occurring during or shortly after infusion, are
usually transient and mild. A cumulative sensory peripheral neuropathy may also develop
with prolonged treatment with oxaliplatin, eventually causing superficial and deep sensory
loss, sensory ataxia, and functional impairment. Studies have shown patients with acute sensory
symptoms to display little or no axonal degeneration. The similarity of acute symptoms induced
by oxaliplatin to those caused by several drugs or toxins acting on neuronal or muscular ion
channels suggests that these symptoms may result from a specific interaction of oxaliplatin
with voltage-gated sodium (Na+) channels. The current recommendations for the management
of the acute and cumulative neurotoxicity from oxaliplatin include education about exposure
to cold, dose modification, “stop and go”, and use of neuromodulatory agents, in particular,
intravenous calcium and magnesium infusion. Upon the approval of oxaliplatin-based regimens
both for adjuvant and metastatic treatment of colon cancer, it is crucial to compile knowledge
about the recognition and management of neurotoxicity from oxaliplatin.
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Introduction
Nearly 150 000 Americans were diagnosed with colorectal cancer in 2004. This disease
accounts for > 50 000 deaths per year and ranks second in cancer-related deaths in
the United States (Jemal et al 2004). Among these cases of colorectal cancer,
approximately 40% of patients had locally advanced disease or metastases not
amenable to surgical resection.
5-fluorouracil (5-FU) has been a mainstay in the treatment of advanced colorectal
cancer since the late 1950s (Midgley and Kerr 1999; Meyerhardt and Mayer 2005).
Along the way, there have been improvements in clinical outcomes with altering
dosing regiments and modulating 5-FU with leucovorin (LV) (Petrelli et al 1989;
Poon et al 1989). Combination therapy with 5-FU-LV was considered standard of
care up until the last decade. More recently, irinotecan and oxaliplatin were found to
have activity in advanced colorectal cancer (Petrelli et al 1989; Poon et al 1989; Hoff
and Pazdur 2004). Irinotecan inhibits topoisomerase
 I, a nuclear enzyme involved in
the unwinding of DNA during
 replication (Hsiang et al 1989). Irinotecan has
demonstrated activity
 against metastatic colorectal cancers when used as monotherapy
(Shimada et al 1993; Conti et al 1996) or in conjunction with 5-FU-LV (Saltz et al
2000).
Oxaliplatin is the only platinum derivative with activity against advanced colorectal
cancer. It binds and cross-links strands of DNA, forming DNA adducts thus inhibiting
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DNA replication and transcription (de Gramont et al 2000).
de Gramont and colleagues (2000) published one of the
initial trials showing the success of using oxaliplatin in
combination with 5-FU-LV as first-line therapy in advanced
colorectal cancer. In that study, 420 previously untreated
patients with colorectal cancer deemed unresectable were
randomized to receive LV followed by bolus and infusion
of 5-FU every 2 weeks (LV5FU2) either alone or with
oxaliplatin
 85 mg/m
2 (FOLFOX4)
 . Patients receiving the
FOLFOX4 regimen had significantly
 longer progression-
free survival (median, 9.0 vs 6.2 months, p = 0.0003) and
better response rate (50.7% vs 22.3%, p = 0.0001), but the
difference in median overall survival did not reach clinical
significance
 when compared to LV5FU2 alone (de Gramont
et al 2000).
Not until recently had there been a head to head
comparison of oxaliplatin-and-irinotecan-containing
regimens in advanced colorectal cancer. Tournigand and
colleagues (2004) provided one of the first published trials
comparing oxaliplatin-and-irinotecan-based regimens. They
set out to investigate two sequences: (1) folinic acid, 5-FU,
and irinotecan (FOLFIRI), followed by folinic acid, 5-FU,
and oxaliplatin (FOLFOX6), and (2) FOLFOX6 followed
by FOLFIRI. The irinotecan-and-oxaliplatin-based regimens
each used bolus 5-FU followed by a 46-hour continuous
infusion. Their results showed that both sequences were
similar in efficacy with median survival being greater than
20 months in both arms (p = 0.99) (Tournigand et al 2004).
In another study by Goldberg et al (2004), 795 patients were
randomly assigned to receive FOLFOX4, irinotecan, and
oxaliplatin (IROX), or irinotecan and bolus 5FU plus LV
(IFL). Their data showed that FOLFOX4 was superior to
the other two regimens in terms of median time to
progression, response rates, and median survival. This study
was unique by showing an increase in median survival in
FOLFOX4 compared to IFL (19.5 months vs 15 months,
p = 0.0001). Paresthesias occurred in 18 out of 258 patients
in the FOLFOX4 arm around cycles eight to ten (Goldberg
et al 2004). Based on these data, the oxaliplatin-containing
regimen was approved as first-line therapy in advanced
colorectal cancer, making oxaliplatin-induced peripheral
neuropathy a growing problem.
Types of neurotoxicity associated
with oxaliplatin
Oxaliplatin is a third generation platinate that differs
structurally from earlier platinates. The antineoplastic
properties of third generation platinum derivatives are based
on platinum chelation with the rigid cyclic structure 1,2-
diaminocyclohexane (DACH) (Graham et al 2000). The
neurotoxicity seen with oxaliplatin can manifest as either
of two distinct syndromes: a transient, acute syndrome that
can appear during or shortly after infusion, and a dose-
limiting, cumulative sensory neuropathy.
Acute, transient neurotoxicity
The acute, transient neurotoxicity observed with oxaliplatin
occurs in nearly all patients. This toxicity is rapid in onset,
occurring during or within hours of infusion. The symptoms
are peculiar in that they are often induced or aggravated by
exposure to cold. There may be manifestations of distal
sensory and motor toxicity. The sensory component consists
of paresthesias and/or dysesthesias in the distal extremities
and/or the perioral region. About 1%–2% of patients will
report a transient cold-induced pharyngolaryngeal
dysesthesia, causing a feeling of difficulty in breathing.
These sensory symptoms are less frequently paralleled by
motor symptoms including: tetanic spasms, fasiculations,
and prolonged muscular contractions. The acute motor
toxicity seen with oxaliplatin has been likened to that of
neuromyotonias, tetrodotoxin, and ethylene glycol
poisoning, which suggests hyperexcitablity of motor
neurons as the mechanism (Golleau et al 2001; Wilson et al
2002).
Chronic, cumulative sensory neuropathy
The dose-limiting, cumulative sensory neurotoxicity is
seen in 10%–15% of patients after cumulative doses of
780–850 mg/m
2 (de Gramont et al 2000; Grothey et al 2002).
Symptoms consist primarily of noncold-related dysesthesias
and paresthesias of the extremities. These symptoms are
quite similar to those seen with cisplatin toxicity, although
ototoxicity is rare with oxaliplatin. Symptoms generally
persist between cycles and increase in intensity with
cumulative dose. Impaired sensation, sensory ataxia, and/
or deficit in fine sensory-motor coordination may ultimately
occur (Grothey 2003). The symptoms may be severe enough
to limit patients from performing their activities of daily
living.
Importantly, these symptoms are consistently reversible
with the majority of patients recovering from grade 3
neurotoxicity to grade 1 or less within 6–12 months of
therapy discontinuation (Brienza et al 1995; Grothey 2003).
In a phase III trial done by de Gramont and colleaguesTherapeutics and Clinical Risk Management 2005:1(4) 251
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(2000), 74% of patients recovered from grade 3. The median
time to recovery was 13 weeks (de Gramont et al 2000).
This reversibility makes the oncologist role pivotal in using
the dosing scheme to manage these side effects.
An atypical presentation of oxaliplatin neurotoxocity is
cited in the literature as manifesting as Lhermitte’s sign
(Taieb et al 2002). Lhermitte’s sign, also referred to as the
barber shop sign, is described as electric shock type
sensation induced by forward flexion of the head. This
occurred in patients who had received high cumulative doses
of oxaliplatin (> 1000 mg/m2).
Grading of neurotoxicity
The unique set of oxaliplatin-induced neurologic events that
patients experience has prompted the development of a
specific neurotoxicity scale to score the duration and severity
of symptoms. Table 1 compares the features of this new
grading system with the National Cancer Institute
neurotoxicity scales.
Pathogenesis
Neurotoxicity has been observed with platinates since the
first drug in the class, cisplatin, was introduced to
oncologists. The neurotoxicity with cisplatin is cumulative
and dose dependent. It is characterized as a distal sensory
neuropathy and may be associated with ototoxicity as well.
Severely affected patients may experience ataxia. The
toxicity with cisplatin is generally not seen until cumulative
doses reach the 300 mg/m
2 range. Recovery is generally slow
and incomplete (Screnci and McKeage 1999). Carboplatin,
a second generation platinate, generally shows dose-limiting
hematologic toxicities. Although it is less frequent,
carboplatin can produce a similar ototoxicity and distal
neuropathy to that seen with cisplatin. Symptoms are
generally less severe and recovery is better (Cavaletti et al
1998; Neijt et al 2000). See Table 2.
The acute sensory neuropathy seen with oxaliplatin is
described in the literature as a “channelopathy”. This is based
on the similarities that oxaliplatin-induced neuropathy
shares with hereditary myotonias and certain toxin
exposures. After an action potential has been elicited, the
fast depolarizing current is dependent upon sodium influx
through voltage-gated ion channels. The action potential is
terminated through sodium channel inactivation coupled
with repolarization by an efflux of potassium ions. Multiple
different sodium channels are expressed in sensory neurons
and each contains different electrical properties. Disorders
of these nerve ion channels are characterized by an increase
or decrease in the excitability of a neuron.
A study by Wu and colleagues (2001) identified a
mutation in a voltage-gated sodium channel in a family with
cold-aggravated myotonia. This mutation led to functional
defects of fast inactivation of the sodium channels
presumably provoking myotonic spells (Wu et al 2001). It
has been shown in rat models that oxaliplatin alters voltage-
gated sodium channels. The effects of oxaliplatin were
studied on rat nerve preparations by Aldersberger et al
(2000), who exposed rat nerves to oxaliplatin. They observed
Table 1 Grading of oxaliplatin-induced neurotoxicity
National Cancer
Institute Oxaliplatin
Scale Neurosensory Sanofi Specific Scale
Grade 1 Mild paresthesia, loss of Paresthesia, dysesthesia of
deep tendon reflexes short duration
Grade 2 Moderate paresthesia, mild Paresthesia, dysesthesia
or moderate objective persisting between cycles
sensory loss
Grade 3 Paresthesia interfering with Paresthesia, dysesthesia
function, severe objective causing functional
sensory loss impairment
Grade 4 Permanent sensory loss
that impairs function
Table 2 Comparison of neurotoxicity profiles of cisplatin and
oxaliplatin
Oxaliplatin
Acute Chronic
Cisplatin neuropathy neuropathy
Incidence 45% 85%–95% In trials 3% in
16%
DLT Yes No Yes
Symptoms Paresthesia, Paresthesia, Paresthesiaa,
sensory ataxia dyesthesia dysethesia,
sens.  Ataxia
Location Extremities Extremities, Extremities
perioral
Trigger None Cold exposure None
Motor symptoms None Rare muscle None
spasms
Onset Delayed Acute Delayed
Recovery Slow, Rapid, Less slow,
incomplete complete more complete
Schedule  
dependence None Yes Probably none
Other Ototoxicity Laryngospasm none
Abbreviations: DLT, dose-limiting toxicities.Therapeutics and Clinical Risk Management 2005:1(4) 252
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an increase in amplitude and duration of compound action
potentials and prolongation of the refractory period of
peripheral nerves. They also noticed that the potassium
current was not altered with the addition of oxaliplatin after
sodium channels were blocked using tetrodotoxin. This was
an important finding, which suggested that the alterations
in the action potential were related to sodium and not
potassium channels. The authors implicate that oxalate, a
known calcium chelator, may play a role in the sodium
channel interaction by chelating calcium; however, they
found no difference in the antagonistic effect of oxaliplatin
on sodium channels at low calcium concentrations
(Aldersberger et al 2000).
The theory that an oxalate affects the sodium channels
has been entertained by other researchers as well. Oxalate
is released intracellularly from oxaliplatin by bicarbonate
ions. Oxalate and 1,2-bis(2-aminophenoxy)ethane-
N,N,N´, N´-tetraacetic acid (BAPTA), another calcium
chelator, have produced effects on inward sodium currents
in invertebrate models similar to those seen with oxaliplatin
(Grolleau et al 2001). See Figure 1.
Unlike the acute transient neuropathy, the cumulative
toxicity of oxaliplatin appears to be related to direct toxicity
to the nerve. Morphological changes have been evident in
dorsal root ganglia in rats treated with cumulative doses of
oxaliplatin intraperitoneally. The treated rats had evidence
of nuclear, nucloeolar, and somatic size reduction on
microscopic examination of the dorsal root ganglia
(Cavaletti et al 2001). These studies have set the framework
for various treatments for oxaliplatin-induced neurotoxicity.
Management of oxaliplatin-
induced neurotoxicity
Prior to oxaliplatin administration, a brief, standardized
neurologic examination should include the testing of
exteroceptive sensation at hands and feet (fine touch, cotton,
pain, pinprick, and deep pressure pain), and testing of
proprioceptive sensation (position of the limbs, Romberg’s
test, perception of passive movements in fingers and toes,
and possibly assessment of vibratory sensation by a tuning
fork or digital device at ankles and wrist). Testing of
Figure 1 Postulated mechanism underlying the pathogenesis of neurotoxicity caused by oxaliplatin. Na
+ channelopathy: the theory that an oxalate affects the sodium
channels has been entertained by other researchers as well. Oxalate is released intracellularly from oxaliplatin by bicarbonate ions. Oxalate and BAPTA, another
calcium chelator, have produced effects on inward sodium currents in invertebrate models similar to those seen with oxaliplatin.
Abbreviations: BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N´, N´-tetraacetic acid; DACH, 1,2-diaminocyclohexane.
NH
NH2
Pt
O
O
C
C
O
O
2
Oxalate hydrolysable ligand Platinum DACH carrier ligand
Ca ++
Oxalate (like BAPTA) chelates 
calcium
Affects inward Na currents 
through Na channels
Structure of Oxaliplatin: An organoplatinum 
complex in which the platinum atom is 
complexed with 1,2-diaminocyclohexane (DACH) 
and with an oxalate ligand as a leaving groupTherapeutics and Clinical Risk Management 2005:1(4) 253
Oxaliplatin-induced neuropathy
osteotendinous reflexes may confirm the presence of sensory
impairment. Patients complaining about difficulties in fine
movements may be asked to perform some tasks such as
buttoning their shirt, lacing their shoes, picking up coins,
or writing a few sentences. Patients who complain about
cold related symptoms could develop “cramps” or
“spasms” if asked to chill a hand in cold water to
assess the presence of muscular contractions, and this should
be avoided.
Methods to treat or prevent oxaliplatin-induced
neurotoxicity center around two main concepts: dosing
strategies and neuromodulatory agents, but educating the
patient and care giver is of utmost importance.
Education
Education of the patients and care givers, including both
physician and nursing staff, about symptoms resulting from
oxaliplatin-induced neurotoxicity is paramount. It is equally
essential that they be familiar with measures to be taken to
manage these events. Patients must be instructed to avoid
exposure to cold objects, environment, and liquids.
Reassurance that the acute symptoms of neurotoxicity are
transient is very important. The profession of the patient,
such as a meat handler, should be considered before offering
such an agent. Additionally, patients should be routinely
questioned on the events or presence of subjective
symptoms. Such questions must be focused on the nature
(paresthesias, dysesthesias, hyperesthesias, pain, numbness,
muscle contractions, and weakness), location (extremities,
perioral area), relationship to cold (if any), time course (onset
in relation to oxaliplatin infusion, duration, transient versus
persistent), and severity (presence of functional impairment).
In case of reported “difficulty breathing” or “laryngo-
spasm”, it is important to distinguish between cold-related
symptoms (pharyngolaryngeal dysesthesia, muscular
contractions) and noncold-related symptoms (muscular
contractions). In the latter case, if a cutaneous rash is present,
a differential diagnosis of acute hypersensitivity associated
with oxaliplatin is mandatory. Checking O2 saturation may
be useful in ruling out the presence of an allergic reaction
associated with Quincke’s edema. Furthermore, this would
substantially help reassure the patient.
Dose modification and change in
schedule
The recent clinical trials with oxaliplatin 85 mg/m2 have
applied an algorithm for oxaliplatin dose reductions in
patients presenting with signs/symptoms of neurotoxicity.
The main decisional criteria for dose reduction were
transience versus persistence of symptoms, relationship of
clinical symptoms to cold, and presence of pain, functional
impairment, and/or sensory abnormalities at neurologic
examination. The leading principle of the algorithm was to
allow for only one dose reduction and to stop treatment until
improvement or recovery (see drug information approved
by FDA and supplied with injection).
The presence of transient paresthesias associated with
pain or functional impairment led to dose lowering from
85 to 75 mg/m
2 when neurologic examination was normal
in adjuvant setting and 65 mg/m2 in the metastatic setting.
If the neurologic examination was abnormal, the cycle of
therapy was omitted with resumption of therapy at the
scheduled next cycle. If paresthesias with pain or functional
impairment persisted between cycles, therapy was
interrupted until improvement was noted, at which time
therapy was resumed at the lower therapeutic dose (see drug
insert supplied with drug). In trials that scheduled oxaliplatin
130 mg/m2 every 3 weeks, the therapeutic dose was reduced
to 100 mg/m
2, with all other parameters remaining the same
(de Gramont et al 2004).
Prolonging the duration of infusion from 2 to 6 hours
can usually prevent recurrence of pharyngolaryngeal
dysesthesia by decreasing the Cmax by an estimated 32%.
In such cases, no dose reduction is not required then.
OPTIMOX (STOP and GO) concept
Observations of reversibility of oxaliplatin-induced
neurotoxicity led de Gramont and colleagues (2000) to
develop a dosing scheme termed the STOP and GO
(OPTIMOX) strategy with the goal of increasing the
cumulative oxaliplatin dose that can be given. This strategy
uses a 5-FU-LV infusion (without bolus) over 46 hours plus
oxaliplatin 130 mg/m
2 every 2 weeks for 6 cycles until a
cumulative dose of 780 mg/m
2 has been achieved. After this,
oxaliplatin is held and treatment with 5FU-LV is continued
in the following fashion: day 1, LV 200 mg/m2 (over
2 hours); bolus 5-FU 400 mg/m
2, infusion of 5-FU
2.4–3.0 mg/m
2 over 46 hours every 2 weeks. The oxaliplatin
is reintroduced after a 6-month hiatus. A phase III study
including 608 patients was presented at the American
Society of Clinical Oncology Meeting in May 2003, which
compared OPTIMOX concept with FOLFOX4. The
OPTIMOX arm showed significantly lower rates of Grade
3 neurotoxicity (13% vs 19%; p = 0.0017) withoutTherapeutics and Clinical Risk Management 2005:1(4) 254
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compromising response rates (RR) or progression free
survival (PFS) (RR 63.1% vs 59.8%; PFS 9.2 vs 8.9 months)
(de Gramont et al 2004). This appears to be a promising
approach to prolong the administration of platinate therapy
without compromising efficacy.
In the MOSAIC study evaluating FOLFOX in the
adjuvant treatment of colon cancer, the main side effect of
FOLFOX4 was also the anticipated sensory neuropathy
(Andre et al 2004). The overall incidence of grade 3
neurotoxicity was 12.4% and 18% among patients who
received the entire planned 1020 mg/m
2 dose of oxaliplatin.
However, the neurotoxicity proved reversible in the vast
majority of patients so that at 12 and 18 months after
discontinuation of therapy only 1.1% and 0.5% of patients,
respectively, had residual grade 3 neurotoxicity (Andre et
al 2004).
In another study conducted by the National Surgical
Adjuvant Breast and Bowel Project (NSABP C-07) and
reported at American Society of Clinical Oncology (ASCO)
(2005) (Wolmark et al 2005), in which 2407 patients were
randomized to either Roswell Park schedule 5FU-LV
(500 mg/m2 of both given weekly for 6 weeks, followed by
2 weeks’ rest for 3 cycles) versus the same 5FU-LV regimen
and oxaliplatin (FLOX) (oxaliplatin at 85 mg/m2 every two
weeks, but only on weeks 1, 3, and 5 of the 8-week cycle;
cumulative dose 765 mg/m
2). Seventy-three percent of
patients received the planned oxaliplatin treatment. The
regimen was tolerable as grade 3 and 4 toxicities were similar
in the two arms (Grade 3/4–50%/10% FLOX vs 41%/9%
5FU-LV). Only 8% of patients experienced grade 3
neurotoxicity and this decreased to 0.5% of patients after
12 months (Wolmark et al 2005).
On the other hand, there are data suggesting that
oxaliplatin dose intensification significantly improves RR
and PFS in pretreated metastatic disease without increasing
severe toxicity. Maindrault-Goebel et al (2000)
retrospectively analyzed data from three phase II studies
using different FOLFOX regimens (FOLFOX2, 3, and 6).
Data on 126/161 patients was included. FOLFOX2 included
oxaliplatin 100 mg/m
2; FOLFOX3, 85 mg/m
2; and
FOLFOX6, 100 mg/m
2. Forty-seven patients received low
dose intensity (LDI) oxaliplatin (LDI: ≤ 85 mg/m2/2 weeks)
and 79 patients high dose intensity (HDI) oxaliplatin (HDI:
> 85 mg/m
2/2 weeks). It was found that the objective
responses occurred in 31 (39%) HDI patients and 9 (19%)
LDI patients (p = 0.03). Median PFS was 28 weeks, with
52% of HDI patients progression free at 6 months, and 26
weeks with 36% of LDI patients progression free at 6 months
(p = 0.02). Increased oxaliplatin dose intensity was not
associated with increased neurotoxicity or other toxicities.
FOLFOX are among the most effective regimens for treating
LV-5-FU-resistant metastatic colorectal cancer. This study
showed that oxaliplatin dose intensification significantly
improves RR and PFS in pretreated metastatic disease
without increasing severe toxicity (Maindrault-Goebel et al
2000).
Neuromodulatory agents
Ca/Mg infusion
Divalent cations have the ability to modify voltage-gated
sodium channels (Gremlin et al 2002). It is hypothesized
that the acute neurotoxicity of oxaliplatin is related to the
ability of oxalate to chelate calcium. Increases in
extracellular calcium have been shown to increase the
probability of sodium channel closure decreasing the
hyperexcitability of peripheral neurons seen in oxaliplatin-
induced neuropathy (Armstrong and Cota 1999).
Magnesium supplementation has been previously studied
in preventing cisplatin-induced hypomagnesemia (Lajer and
Daugaard 1999).
This promising treatment is based on a retrospective
study by Gamelin and colleagues (2004) of 161 patients
treated with varying regimens of oxaliplatin and 5FU-LV.
Patients had received one of three various oxaliplatin
regimens (85 mg/m
2/2 weeks; 100 mg/m
2/2 weeks; or
130 mg/m2/3 weeks). Ninety-six patients received 1 g each
of calcium gluconate and magnesium sulfate intravenously
over 15 minutes just before the oxaliplatin infusion. This
dose was repeated after completion of the infusion. The
percentage of patients with grade 3 distal paresthesias was
significantly lower in the Ca/Mg group (7% vs 26%,
p = 0.001). The acute symptoms of distal and perioral
paresthesias were much less frequent. No patients in the
Ca/Mg group experienced pseudolaryngospasm.
Furthermore, the Ca/Mg group recovered more rapidly from
neuropathy especially in the patients receiving 85 mg/m
2 of
oxaliplatin (< 2 months). The Ca/Mg infusions had no
bearing on treatment efficacy (Gamelin et al 2004). This is
a simple strategy to help ameliorate the symptoms of acute
oxaliplatin-induced neuropathy, but further investigation is
warranted to determine if this treatment is effective in
preventing chronic, cumulative neurotoxicity. It must be
borne in mind that this strategy is based on a single
retrospective analysis of a nonrandomized study.
Prospective, randomized studies (such as the CONCEPTTherapeutics and Clinical Risk Management 2005:1(4) 255
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study) are underway to validate the benefit of these minerals
in ameliorating the neurotoxicity of oxaliplatin.
We recently reported on a case of a patient in which oral
calcium supplements not only was successful in treating
his neurotoxicity, but also the patient was able to receive a
cumulative dose of 2500 mg/m2 (990 mg/m2 with oral
calcium only) (Saif 2004).
Glutathione
Glutathione, an important biological antioxidant, is able to
prevent the accumulation of platinum adducts in the dorsal
root ganglia in rat model (Holmes et al 1998). A single
randomized, double-blind, placebo-controlled trial has been
done assessing the efficacy of glutathione in the prevention
of oxaliplatin-induced neurotoxicity (Cascinu et al 2002).
Fifty-two patients were randomized to receive a 1500 mg/m
2
glutathione infusion over 15 minutes or normal saline before
oxaliplatin infusion. Oxaliplatin was administered on a
bimonthly regimen. The median cumulative dose of
oxaliplatin did not differ among the two arms. The
glutathione group showed significantly less grade 2 or higher
neurotoxicity after 8 cycles of chemotherapy (58% vs 10%).
The response rates were similar between the glutathione
and placebo groups (26.9% vs 23.1%), suggesting that
glutathione does not change the efficacy of oxaliplatin. This
finding was of significant importance since glutathione has
been shown to affect the efficacy of a variety of anti-
neoplastic interventions (Arrick and Nathan 1984).
Carbamazepine
The theory that oxaliplatin affects voltage-gated sodium
channels has led to the use of carbamazepine, a widely used
anticonvulsant, to prevent oxaliplatin-induced neuropathy.
Carbamazepine decreases high frequency repetitive firing
of action potentials by enhancing sodium-channel
inactivation (Macdonald and Kelly 1995). In a small German
study, 40 patients refractory to 5-FU were treated with
oxaliplatin, 5-FU, and folinic acid as second line
therapy (Eckel et al 2003). Ten patients were additionally
treated with carbamazepine maintaining serum levels of
3–6 mg/L. The patients in the carbamazepine group were
able to receive significantly higher cumulative doses of
oxaliplatin (722 mg/m2 vs 510 mg/m2; p = 0.02). No
neuropathy higher than grade 1 occurred in the carba-
mazepine group compared with 30% in the control group.
Larger trials need to be conducted to make conclusions about
the prophylactic efficacy of carbamazepine in oxaliplatin-
induced neuropathy; however, initial data is promising.
Gabapentin
Gabapentin, another widely used anticonvulsant, appears
to affect the release of gamma-aminobutyric acid (GABA).
The side effect profile and therapeutic index of gabapentin
make it more tolerable and easier to administer than
carbamazepine, thus making it more attractive to use for
prophylaxis of oxaliplatin-induced neurotoxicity. In a pilot
study, 15 patients were treated with oxaliplatin (85 mg/m2/d
every 2 weeks) plus 5-FU, and folinic acid as second therapy
for advanced colorectal cancer (Mariani et al 2000).
Gabapentin at a dose of 200 mg/d was started at the onset of
neuropathic symptoms. If the patients’ symptoms did not
resolve in a period of 3 days, then the dose was increased to
300 mg/d. All patients treated with gabapentin had resolution
of their symptoms, and no patients had to stop therapy
secondary to neurotoxicity. In another study presented at
ASCO (2005), 115 patients with chemotherapy-induced
peripheral neuropathy (for ≥ 1 month, with average pain
rating of ≥ 4/10 or Eastern Cooperative Oncology Group
[ECOG] sensory neuropathy ≥ 1/3) were randomized in a
double-blind, placebo-controlled trial to either: gabapentin
(target dose = 900 mg three times a day [TID]) for 6 weeks
then crossover to placebo for 6 weeks (n = 57) or treatment
in the reverse order (n = 58) (Wong et al 2005). A 2-week
washout occurred between crossover treatments. The co-
primary endpoints were the average daily pain numerical
analogue intensity rating (0 = no pain to 10 = worst pain
imaginable) and the ECOG toxicity rating for sensory
neuropathy (0 = none to 3 = severe). The results of the study
showed that gabapentin did not significantly improve the
co-primary endpoints of pain intensity (–0.5 vs –1.0 change
from baseline to week 6 for patients on gabapentin and
placebo respectively, p = 0.18) or the ECOG toxicity rating
for sensory neuropathy (–0.2 vs –0.1 for gabapentin and
placebo respectively, p = 0.38). Patients on gabapentin
reported significantly more nystagmus (p = 0.009) and
dizziness (p = 0.02). Therefore, the study was not able to
confirm the benefit of the use of gabapentin in ameliorating
peripheral neuropathy.
Amifostine
Based on the studies of amifostine with cisplatin, its effect
has been studied with oxaliplatin. Twenty-one patients with
peripheral neuropathies (grade ≥ 2) were treated with
amifostine 200 mg/m
2 subcutaneously (SC) over 3 minutes,
twice a week for 6 weeks (Penz et al 2001). Patients were
continued on amifostine for as long as improvement was
seen. At study entry, 8 patients had grade 3 neurotoxicityTherapeutics and Clinical Risk Management 2005:1(4) 256
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and 12 patients had grade 2 neurotoxicity. Among seventeen
evaluable patients who completed at least 6 weeks of
amifostine therapy, 12 of 17 (71%) patients showed at least
minimal (1 grade) improvement in their peripheral
neuropathy. One patient reported an increase in peripheral
neuropathy from grade 1 to grade 2. Toxicities were
manageable with no grade 3 or 4 toxicities observed. Grade
1 or 2 toxicities included: nausea (33%, n = 7); fatigue (9%,
n = 2); hypotension (5%, n = 1); and sneezing (5%, n = 1).
Other neuromodulatory agents
Other agents including acetyl-L-carnitine (ALCAR), and
α-lipoic acid have shown some promise in small trials.
Maestri et al (2002) presented at ASCO (2002) a study
evaluating the role of ALCAR in the management of
neurotoxicity associated with oxaliplatin. They found that
ALCAR was effective in treating patients with established
chemotherapy-induced peripheral neuropathy (Maestri et
al 2002). Twenty patients were followed with neurotoxicity
defined by the WHO criteria. The patients had been treated
with various agents including platinum compounds, taxanes,
and vinca alkaloids. All were treated with ALCAR 1 g
infusion over 1–2 hours for at least 10 days. Sixteen of 20
patients showed at least one grade improvement in their
peripheral neuropathy.
Similarly α-lipoic acid has shown beneficial effects in
patients with established platinum-induced chemotherapy
(Gedlicka et al 2002). In a study of 15 patients, neurologic
symptoms improved (by at least one grade) in seven patients
with grade 2 peripheral neuropathy and in one patient who
suffered from
 grade 3 symptoms. The median time to
response was 4 weeks (range, 3–12 weeks), and the median
duration of treatment with α-lipoic
 acid was 2 months (range,
1–4 months).
Ginkgo biloba extract
Ginkgo biloba (GB) is a neuroprotective agent used in
neurodegenerative diseases. The possible mode of action
may include the prevention of uncoupling of oxidative
phophorylation and protection of cell membrane through
free radical scavenging (Marshall et al 2004). Preclinical
data support the anticancer benefit of GB through targeted
inhibition of peripheral-type benzodiazepine receptors over-
expressed on mitochondrial membranes in many tumors
including colon cancer. There are also data suggesting that
GB synergizes with chemotherapy in addition to potential
prevention of neurotoxicity. Georgetown University
conducted a retrospective analysis of 17 patients with
colorectal cancer who were treated with either FOLFOX or
CAPEOX regimens (Marshall et al 2004). Ginkgo Biloba
was added to chemotherapy at the dose of 120 mg orally
bid and Ca or Mg was not given. Eleven of 17 patients
initiated GB at cycle 1 or 2 of treatment, only reporting
grade 1 acute neuropathy limited to less than 6 days, and
9/11 patients lasted only 2–3 days. The other 6 patients
initiated GB after cycle 2, and 5/6 patients noticed decreased
intensity and duration in neuropathy with the use of GB.
Laryngospasm was not observed in any patient on GB. No
GB-related side effects have been observed.
Celecoxib
In a recent study, celecoxib 200 mg bid was added to
the regimen consisting of continuous infusion 5-FU
200 mg/m
2/d for 10 weeks with a 2-week break and
oxaliplatin 130 mg/m
2 every 3 weeks (CIFOX). Among 263
patients, 73 patients received celecoxib and 179 did not
(Agafitei et al 2004). Patients on both regimens had similar
characteristics. None of the 73 patients who received
celecoxib experienced any grade 3 or 4 neurotoxicity,
compared with 10 of the 179 patients who did not receive
celecoxib (p = 0.024). The patients who received celecoxib
were less likely to experience grade 3 or 4 neuropathy (0%
vs 6%) but more likely to experience grade 1 neuropathy
(67% vs 48%) than those who did not receive celecoxib.
Pharmacogentics
It is postulated that variations in genes potentially involved
in the detoxification (glutathione system: glutathione-S-
transferase genes P1 [GSTP1], glutathione-S-transferase
genes M1 [GSTM1]) or the cytotoxic mechanism
(nucleotide excision repair: excision repair cross-
complementing rodent repair deficiency, complementation
group 2 [ERCC2], x-ray repair cross-complementing group
1 protein [XRCC1]) of oxaliplatin could serve as genetic
predictors of susceptibility to oxaliplatin’s neurotoxic
effects. This concept was tested by extracting germline DNA
from whole blood of 299 patients who received FOLFOX4
in the Intergroup study N9741 (Grothey et al 2005). Four
genetic variants (GSTP1 I105V, GSTM1 del, ERCC2
K751Q, XRCC1 R399Q) were tested for association with
the time to development of grade 2/3 sensory neuropathy
(sNT) and sNT as reason for treatment discontinuation. In
addition, patients who developed grade 2 (3) neurotoxicity
before a cumulative oxaliplatin dose of 600(800) mg/m2 wasTherapeutics and Clinical Risk Management 2005:1(4) 257
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reached were compared to an equal number of patients that
tolerated extremely high cumulative doses of oxaliplatin.
The study showed that the patients with GSTP1 I105V C/C
polymorphism were more likely to discontinue FOLFOX
due to sNT (23.7%) than patients with T/T (9.2%) or C/T
(10%) variants (p = 0.039). Patients with GSTP1 I105V C/
C also had lower cumulative dose to onset of grade 3 sNT
compared to T/T or C/C pts (p = 0.05). Patients carrying at
least one GSTP1 I105V C-allele (C/C or C/T) were more
likely to experience rapid onset grade 3 neurotoxicity than
T/T patients, who were more likely to be able to tolerate
high doses (p = 0.027 for grade 2, p = 0.03 for grade 3). No
significant correlation of GSTM1, ERCC2, and XRCC1
polymorphisms with the onset of sNT on FOLFOX was
observed. This study offers an early evidence that genetic
variations in GSTP1 may serve as predictors of susceptibility
to oxaliplatin-mediated sNT. Such findings should be
validated in prospective studies so that GSTP1 poly-
morphisms can be used to identify patients in whom
neurotoxicity prevention strategies on oxaliplatin-based
chemotherapy are warranted.
Conclusion
Oxaliplatin, a third generation platinum compound, has been
shown to be effective as first line therapy in advanced
colorectal cancer. Neurotoxicity is the dose-limiting side
effect with this drug. This side effect can manifest as two
distinct forms: the acute, reversible sensory neuropathy and
a chronic, cumulative neuropathy. The acute form occurs
with infusion or in the ensuing hours. The chronic toxicity
does not become apparent until cycles 8–10 in the commonly
used FOLFOX dosing regimen, making it more predictable.
The treatment of oxaliplatin-induced neurotoxicity needs
to start at the bedside. Nursing staff and oncologists should
inform patients to avoid contact with cold objects, food,
and beverages. This can prevent paresthesias and more
importantly pseudolaryngospasm. Promising strategies exist
that include dosing modification and neuromodulatory
agents, although larger trials need to be conducted to confirm
efficacy.
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